A method of deploying an ocular implant into Schlemm's canal of an eye. The method includes the steps of inserting a distal end of a cannula through a cornea of the eye and into an anterior chamber of the eye, the cannula having a distal opening extending from the distal end and through a side wall; placing the distal opening of the cannula into fluid communication with Schlemm's canal; advancing the ocular implant distally through the cannula with a delivery tool engaged with the ocular implant, a proximal portion of the ocular implant engaging the delivery tool proximal to a distal portion of the delivery tool; and disengaging the ocular implant and the delivery tool when the proximal portion of the ocular implant reaches the cannula distal opening. The invention also includes a system for practicing the method.

A fluid dispensing device includes a light source, and a nozzle spaced from the light source. The device also includes a membrane positioned within a beam path of the light source, where the membrane is configured to allow a portion of light from the light source through to the nozzle. The device also includes a fluid chamber positioned between the membrane and the nozzle, where the nozzle is configured to allow a beam of the portion of light to pass through along the beam path, and where the nozzle is further configured to form a stream of fluid expelled from the fluid chamber along the beam path.

Embodiments of the present disclosure relate to methods and apparatus relating to corneal collagen crosslinking (CXL). In some embodiments, disclosed methods and apparatus provide boosted oxygen diffusion into corneal stroma and make possible efficacious accelerated CXL using a non-contact apparatus that reduces use of disposable supplies. In some embodiments, increased atmospheric oxygen concentration around a corneal outer surface occurs, which increases oxygen diffusion into stroma. Accordingly, in some embodiments, increased CXL efficacy occurs as well as reduced overall procedure time.

An ophthalmic composition can include dexamethasone phosphate, or a salt thereof, dexamethasone, but in an amount not greater than 1.0 wt % relative to the amount of dexamethasone phosphate, or a salt thereof, and water. The ophthalmic composition can have a pH of about 5 to about 8 and a tonicity of from about 100 mOsm/kg to about 760 mOsm/kg.

An aid for dispensing eye drops to improve adherence. The aid, which may be integrated into an eye drop bottle (10) or be separately attached, aligns the eye drop container to better dispense eye drops, while resting the engagement surface (55) of an alignment structure (50) upon the bridge of a user's nose (80), supporting the eye drop container and not intruding upon the temporal half of the field of view of the user's eye.

This invention relates to a Nanostructured Lipid Carrier (NLC) particle comprising a therapeutic agent encapsulated therein for ocular delivery of the therapeutic agent, wherein the Nanostructured Lipid Carrier comprises: (i) a solid outer shell comprising a solid lipid, and (ii) a liquid core comprising a liquid lipid; and wherein the core comprises the therapeutic agent. Compositions of the NLC particles, use of the NLC particles, methods of treatment or prevention of an eye disorder and an eye drop dispenser are also provided.

A lenticular label for attachment to a surface of a medical device to be used in a pre-set orientation is disclosed. The lenticular label has a first face with a lens structure and a second face including a lenticular graphic resulting from a composition of a plurality of images. The images are aligned with the lens structure so that a different visual impression is obtained by changing a viewing angle from which the lenticular graphic is viewed with respect to the first face. The plurality of images includes a compliance image. The lens structure is arranged such that the compliance image is visible by a user when the lenticular label is attached to the medical device and the medical device is in the pre-set orientation. A medical device with such a lenticular label, and methods of use thereof are also disclosed.

Disclosed herein are improved dispensing devices for facilitating application of eye drops that are ergonomic, promote improved patient adherence, and eliminate the need for extraneous gadgets or facilitating devices that may add additional expense to users. A dispensing device can include a container body for storing drops and a nozzle coupled to the body for dispensing the drops. The device can include one or more channels defined on a surface of the container body and configured to couple, or otherwise mount or abut, to an anatomical structure of a user (such as, for example, a user's nose bridge or eyebrow ridge). The device can also include one or more grip areas defined on the container body and configured to allow a user to generally hold the device and to apply force thereto to dispense drops from the device.

An implant placed into the lacrimal gland of a patient for delivery of a drug to the eye for treating conditions such as glaucoma, or merely the gland itself for treating dry eye syndrome. The implant can be placed in such a way that the drug-carrying surfaces of the implant are exposed to the glandular tissues allowing diffusion of the drug into those tissues. For glaucoma, tears generated by those tissues can contain an amount of the drug for delivery to the surface of the eye. The implant can be made from biodegradable/bioabsorbable or non-biodegradable/non-bioabsorbable materials. A tool and method of use facilitates proper emplacement of the implant in part of the lacrimal gland. The tool can include a hallow needle having an axial bore through which the implant passes. During emplacement, a ramrod connected to a physician-manipulable plunger on a syringe-like device pushes the implant from the tip of the needle. Physical structures on the implant can help properly release the drug carried by the implant and help maintain its position in the lacrimal gland.

A method includes inserting a flexible cannula between a sclera and a choroid of an eye. The needle is advanced from a distal end of the flexible cannula, such that the needle pierces the choroid to access a subretinal space of the eye. The needle is used to deliver a first volume of leading bleb fluid to the subretinal space. The delivery of leading bleb fluid is ceased for a duration of time. After expiration of the duration of time, the needle is used to deliver a second volume of the leading bleb fluid to the subretinal space. The combination of the delivered first and second volumes of the leading bleb fluid causes a substantial portion of the retina to detach from the choroid. A therapeutic agent may then be delivered to the subretinal space in the region where the retina is detached from the choroid.